(Q40176328)

18 September 2017

title

Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma (English)

1 reference

18 September 2017

1 reference

O Weigert

1

1 reference

18 September 2017

A Pastore

2

1 reference

18 September 2017

M Rieken

3

1 reference

18 September 2017

N Lang

4

1 reference

18 September 2017

W Hiddemann

5

1 reference

18 September 2017

M Dreyling

6

1 reference

18 September 2017

publication date

1 February 2007

1 reference

18 September 2017

1 reference

18 September 2017

volume

21

1 reference

18 September 2017

issue

3

1 reference

18 September 2017

page(s)

524-528

1 reference

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

The ubiquitin-proteasome proteolytic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

The proteasome: a suitable antineoplastic target

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Generalized Equations for the Analysis of Inhibitions of Michaelis-Menten and Higher-Order Kinetic Systems with Two or More Mutually Exclusive and Nonexclusive Inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

High-dose cytosine arabinoside in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Mechanisms of apoptosis induction by nucleoside analogs.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Caspase activation inhibits proteasome function during apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404511

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404511

1 reference

Dimensions Publication ID

18 September 2017

1040447192

0 references

Fatcat ID

release_l2tddaavbfeidagfvyhcxbvqsq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/l2tddaavbfeidagfvyhcxbvqsq

24 November 2022

mapped directly with Wikidata item

1 reference